UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abu, A., Naqvi, T., Mohammad, T., & Hasan, G. M. (2018). *Advancements in Docking and Molecular Dynamics Simulations Towards Ligand-receptor Interactions and Structure-function Relationships*. 1755–1768. https://doi.org/10.2174/1568026618666181025114157

Ahuja, S., Khan, A. A., & Zaheer, S. (2024). Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2. *Pathology Research and Practice*, *262*(June), 155550. https://doi.org/10.1016/j.prp.2024.155550

Aron, L. (2010). *An online survival analysis tool to rapidly assess the effect of 22 , 277 genes on breast cancer prognosis using microarray data of 1 , 809 patients*. 725–731. https://doi.org/10.1007/s10549-009-0674-9

Aziz, N., Kim, M. Y., & Cho, J. Y. (2018). Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. *Journal of Ethnopharmacology*, *225*(May), 342–358. https://doi.org/10.1016/j.jep.2018.05.019

Bahuguna, A., Khan, I., Bajpai, V. K., & Kang, S. C. (2017). MTT assay to evaluate the cytotoxic potential of a drug. *Bangladesh Journal of Pharmacology*, *12*(2), 115–118. https://doi.org/10.3329/bjp.v12i2.30892

Banerjee, K., Resat, H., & Gene, T. (2017). *HHS Public Access*. *138*(11), 2570–2578. https://doi.org/10.1002/ijc.29923.Constitutive

Barrett, T., Beck, J., Benson, D. A., Bollin, C., Bolton, E., Bourexis, D., Brister, J. R., Bryant, S. H., Canese, K., Clark, K., Dicuccio, M., Dondoshansky, I., Federhen, S., Feolo, M., Funk, K., Geer, L. Y., Gorelenkov, V., Hoeppner, M., Holmes, B., … Zbicz., K. (2015). Database resources of the National Center for Biotechnology Information. *Nucleic Acids Research*, *43*(D1), D6–D17. https://doi.org/10.1093/nar/gku1130

Basar, E., Walch, M., & Lieberman, J. (2016). *with 3 ' Uridylated Intermediates Degraded by DIS3L2*. *11*(7), 1079–1089. https://doi.org/10.1016/j.celrep.2015.04.026.Apoptosis

Basheeruddin, M., & Qausain, S. (2024). *Hypoxia-Inducible Factor 1-Alpha (HIF-1 α) and Cancer : Mechanisms of Tumor Hypoxia and Therapeutic Targeting*. *2024*(10), 1–18. https://doi.org/10.7759/cureus.70700

Bayoumi, D., ELagamy, A. A. E. D., Salem, H. S. M., & Elboghdady, A. (2024). Predictors of breast cancer HER2-receptor positivity by MRI intuitive imaging features. *Egyptian Journal of Radiology and Nuclear Medicine*, *55*(1), 1–11. https://doi.org/10.1186/s43055-024-01373-1

Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., & Manzione, L. (2007). symposium article Lapatinib in breast cancer. *New Trends in Clinical Oncology - 9th National GOIM Congress 17-19 June 2007, Potenza, Italy*, *18*(Supplement 6), vi26–vi30. https://doi.org/10.1093/annonc/mdm220

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Bissantz, C., Kuhn, B., & Stahl, M. (2010). *A Medicinal Chemist ' s Guide to Molecular Interactions*. 5061–5084. https://doi.org/10.1021/jm100112j

Boyd, N., Berman, H., Zhu, J., Martin, L. J., Yaffe, M. J., Chavez, S., Stanisz, G., Hislop, G., Chiarelli, A. M., Minkin, S., & Paterson, A. D. (2018). The origins of breast cancer associated with mammographic density: A testable biological hypothesis. *Breast Cancer Research*, *20*(1), 1–13. https://doi.org/10.1186/s13058-018-0941-y

Cao, D., Zhu, G.-Y., Lu, Y., Yang, A., Chen, D., Huang, H.-J., Peng, S.-X., Chen, L.-W., & Li, Y.-W. (2020). Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. *Biomedicine & Pharmacotherapy*, *129*, 110462. https://doi.org/https://doi.org/10.1016/j.biopha.2020.110462

Cao, K., Abbassi, L., Romano, E., & Kirova, Y. (2021). Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. *Expert Review of Anticancer Therapy*, *21*(5), 501–510. https://doi.org/10.1080/14737140.2021.1868993

Çetinkaya, M., & Baran, Y. (2023a). Therapeutic Potential of Luteolin on Cancer. *Vaccines*, *11*(3). https://doi.org/10.3390/vaccines11030554

Çetinkaya, M., & Baran, Y. (2023b). *Therapeutic Potential of Luteolin on Cancer*.

Chang, C., Chan, H., Lin, H., Way, T., Kao, M., Song, M., Lin, Y., & Lin, C. (2012). *Rhein Induces Apoptosis in Human Breast Cancer Cells*. *2012*. https://doi.org/10.1155/2012/952504

Chen, C.-Y., Peng, W.-H., Tsai, K.-D., & Hsu, S.-L. (2007). Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. *Life Sciences*, *81*(23–24), 1602–1614. https://doi.org/10.1016/j.lfs.2007.09.028

Chen, P., Zhang, J., Sha, B., Ma, Y., & Hu, T. (2017). *Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450*. *8*(16), 27471–27480.

Chen, S., Liao, D., Chen, C., Wang, T., & Chen, K. (2019). Construction and Analysis of Protein-Protein Interaction Network of Heroin Use Disorder. *Scientific Reports*, *March*, 1–9. https://doi.org/10.1038/s41598-019-41552-z

Chen, Y., Tripathi, L. P., & Mizuguchi, K. (2011). *TargetMine , an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery*. *6*(3). https://doi.org/10.1371/journal.pone.0017844

Chervoneva, I., Freydin, B., Hyslop, T., Waldman, S. A., & Therapeutics, E. (2018). *HHS Public Access*. *27*(20110195415), 2581–2595. https://doi.org/10.1177/0962280216683204.Modeling

Chiang, C., Way, T., & Lin, J. (2007). *Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21 WAF1 / CIP1*

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

expression with rapamycin. *6*(1), 2127–2138. https://doi.org/10.1158/1535-7163.MCT-07-0107

Chou, T. (2010). *Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method*. *70*(2), 440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947

Cobb, A. N., Czaja, R., Jorns, J., & Cortina, C. S. (2024). Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations. *Current Breast Cancer Reports*, *16*(2), 150–160. https://doi.org/10.1007/s12609-024-00541-6

Colomer, R., Brunet, J., & Menendez, J. A. (2008). *original article*. *February*, 1097–1109. https://doi.org/10.1093/annonc/mdm589

Comşa, Ş., Cîmpean, A. M., & Raica, M. (2015). *The Story of MCF-7 Breast Cancer Cell Line : 40 years of Experience in Research*. *3154*, 3147–3154.

Connell, C. M., & Doherty, G. J. (2017). Activating HER2 mutations as emerging targets in multiple solid cancers. *ESMO Open*, *2*(5), 1–11. https://doi.org/10.1136/esmoopen-2017-000279

Consortium, T. G. O. (2026). The Gene Ontology knowledgebase in 2026. *Nucleic Acids Research*, *54*(D1), D1779–D1792. https://doi.org/10.1093/nar/gkaf1292

D'Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R. (2015). Mechanisms of lapatinib resistance in HER2-driven breast cancer. *Cancer Treatment Reviews*, *41*(10), 877–883. https://doi.org/10.1016/j.ctrv.2015.08.001

Davis, A. P., Johnson, R. J., Lennon-hopkins, K., Sciaky, D., Rosenstein, M. C., Wiegers, T. C., & Mattingly, C. J. (2012). *Original article Targeted journal curation as a method to improve data currency at the Comparative Toxicogenomics Database*. *2012*, 1–13. https://doi.org/10.1093/database/bas051

Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021). *Activation of PI3K / AKT / mTOR Pathway Causes Drug Resistance in Breast Cancer*. *12*(March), 1–16. https://doi.org/10.3389/fphar.2021.628690

Dunkel, M., Gu, S., Ahmed, J., Wittig, B., & Preissner, R. (2008). *SuperPred : drug classification and target prediction*. *36*(May), 55–59. https://doi.org/10.1093/nar/gkn307

Eustace, A. J., Conlon, N. T., McDermott, M. S. J., Browne, B. C., O'Leary, P., Holmes, F. A., Espina, V., Liotta, L. A., O'Shaughnessy, J., Gallagher, C., O'Driscoll, L., Rani, S., Madden, S. F., O'Brien, N. A., Ginther, C., Slamon, D., Walsh, N., Gallagher, W. M., Zagozdzon, R., … Crown, J. (2018). Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. *BMC Cancer*, *18*(1), 1–14. https://doi.org/10.1186/s12885-018-4852-1

Fernando, P. D. S. M., Ko, D. O., Piao, M. J., Kang, K. A., Herath, H. M. U. L., &

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Hyun, J. W. (2024). Protective effect of luteolin against oxidative stress-mediated cell injury via enhancing antioxidant systems. *Molecular Medicine Reports*, *30*(1). https://doi.org/10.3892/mmr.2024.13244

Foucquier, J., & Guedj, M. (2015). *Analysis of drug combinations : current methodological landscape*. https://doi.org/10.1002/prp2.149

Gallo, K., Goede, A., Preissner, R., & Gohlke, B. (2022). *SuperPred 3 . 0 : drug classification and target prediction — a machine learning approach*. *50*(May), 726–731.

Gao, G., Ge, R., Li, Y., & Liu, S. (2019). Luteolin exhibits anti-breast cancer property through up-regulating miR-203. *Artificial Cells, Nanomedicine and Biotechnology*, *47*(1), 3265–3271. https://doi.org/10.1080/21691401.2019.1646749

Gfeller, D., Wirth, M., Daina, A., Michielin, O., & Zoete, V. (2014). *SwissTargetPrediction : a web server for target prediction of bioactive small molecules*. *42*(May), 32–38. https://doi.org/10.1093/nar/gku293

Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020). Towards personalized treatment for early stage HER2-positive breast cancer. *Nature Reviews Clinical Oncology*, *17*(4), 233–250. https://doi.org/10.1038/s41571-019-0299-9

Gradishar, W. J. (2015). Optimizing treatment of HER2-positive breast cancer. *JNCCN Journal of the National Comprehensive Cancer Network*, *13*(5), 649–651. https://doi.org/10.6004/jnccn.2015.0193

Green, D. R. (2022). *The Mitochondrial Pathway of Apoptosis Part II : The BCL-2 Protein Family*. *C*, 1–24. https://doi.org/10.1101/cshperspect.a041046

Grela, E., Kozłowska, J., & Grabowiecka, A. (2018). Current methodology of MTT assay in bacteria – A review. *Acta Histochemica*, *120*(4), 303–311. https://doi.org/10.1016/j.acthis.2018.03.007

Guedes, I. A., Magalhães, C. S. De, & Dardenne, L. E. (2014). *Receptor – ligand molecular docking*. 75–87. https://doi.org/10.1007/s12551-013-0130-2

Gulati, I., Tripathi, S., & Tiwari, S. S. (2024). Biostatistical Investigation Using Docking Mechanism and Its Database to Investigate Drug Design, Drug Discovery, Drug Metabolism and Prediction Via Drug–Drug Interactions. In *Industrial Microbiology and Biotechnology: an Insight into Current Trends* (pp. 357–386). https://doi.org/10.1007/978-981-97-1912-9_15

Gupta, P., & Srivastava, S. K. (2014). *ScienceDirect HER2 mediated de novo production of TGF b leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer 5. 8*. https://doi.org/10.1016/j.molonc.2014.06.006

Gupta, R., Gupta, S., Antonios, B., Ghimire, B., Jindal, V., Deol, J., Gaikazian, S., Huben, M., Anderson, J., Stender, M., & Jaiyesimi, I. (2022). Therapeutic landscape of advanced HER2-positive breast cancer in 2022. *Medical*

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Oncology, *39*(12), 1–14. https://doi.org/10.1007/s12032-022-01849-y

Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A., & Mckusick, V. A. (2005). *Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders*. *33*, 514–517. https://doi.org/10.1093/nar/gki033

Hermawan, A., Ikawati, M., Jenie, R. I., Khumaira, A., Putri, H., Nurhayati, I. P., Angraini, S. M., & Muflikhasari, H. A. (2021). Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. *Saudi Pharmaceutical Journal*, *29*(1), 12–26. https://doi.org/10.1016/j.jsps.2020.12.002

Hermawan, A., Ikawati, M., Khumaira, A., Putri, H., Jenie, R. I., Angraini, S. M., & Muflikhasari, H. A. (2021). Bioinformatics and in vitro studies reveal the importance of p53, PPARG and notch signaling pathway in inhibition of breast cancer stem cells by hesperetin. *Advanced Pharmaceutical Bulletin*, *11*(2), 351–360. https://doi.org/10.34172/apb.2021.033

Hermawan, A., Satria, D., Hasibuan, P. A. Z., Huda, F., Tafrihan, A. S., Fatimah, N., & Putri, D. D. P. (2024). Identification of potential target genes of cardiac glycosides from Vernonia amygdalina Delile in HER2+ breast cancer cells. *South African Journal of Botany*, *164*, 401–418. https://doi.org/10.1016/j.sajb.2023.12.002

Hermawan, A., Windarsih, A., Putri, D. D. P., & Fatimah, N. (2025). LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells. *Journal of Pharmaceutical and Biomedical Analysis*, *253*(March 2024), 0–1. https://doi.org/10.1016/j.jpba.2024.116528

Hernández-valencia, J., García-villarreal, R., Rodríguez-jiménez, M., Hernández-avalos, A. D., Rivero, I. A., Vique-sánchez, J. L., Chimal-vega, B., Pulido-capiz, A., & García-gonzález, V. (2025). *Lapatinib-Resistant HER2 + Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K / PDCD4 Pathways and Calcium Management , Influence of Cryptotanshinone*. 1–21.

Hiatt, R. A., Engmann, N. J., Balke, K., & Rehkopf, D. H. (2020). A complex systems model of breast cancer etiology: The paradigm II conceptual model. *Cancer Epidemiology Biomarkers and Prevention*, *29*(9), 1720–1730. https://doi.org/10.1158/1055-9965.EPI-20-0016

Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M., & Parsons, R. E. (2014). PTEN function: the long and the short of it. *Trends in Biochemical Sciences*, *39*(4), 183–190. https://doi.org/10.1016/j.tibs.2014.02.006

Huang, B., Lang, X., & Li, X. (2022). *The role of IL-6 / JAK2 / STAT3 signaling pathway in cancers*. *December*, 1–14. https://doi.org/10.3389/fonc.2022.1023177

Huang, J., & Xie, Z. F. (2022). Identification of SSBP1 as a prognostic marker in

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

human lung adenocarcinoma using bioinformatics approaches. *Mathematical Biosciences and Engineering*, *19*(3), 3022–3035. https://doi.org/10.3934/mbe.2022139

Huang, L., Jin, K., & Lan, H. (2019). Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. *Oncology Letters*, *17*(4), 3842–3850. https://doi.org/10.3892/ol.2019.10052

Imran, M., Rauf, A., Abu-Izneid, T., Nadeem, M., Shariati, M. A., Khan, I. A., Imran, A., Orhan, I. E., Rizwan, M., Atif, M., Gondal, T. A., & Mubarak, M. S. (2019). Luteolin, a flavonoid, as an anticancer agent: A review. *Biomedicine and Pharmacotherapy*, *112*(January). https://doi.org/10.1016/j.biopha.2019.108612

Ira Cinta Lestari, a* Ramadhan Bestari, b Dewi Pangestuti, b S. E. M. c aBagian. (2025). *HIPOXIA-INDUCIBLE FACTOR 1 (HIF-1) DAN ANGIOGENESIS TUMOR: MEKANISME, IMPLIKASI KLINIS, DAN POTENSI TERAPI*. *VIII*(Ii), 143–155.

Isaza, C. E., Rodriguez, C., Uribe, L., Perez, H. A., Salinas, J., & Cabrera-Rios, M. (2011). The use of central composite designs to improve cytotoxicity data generation: a case study. *IIE Transactions on Healthcare Systems Engineering*, *1*(4), 226–231. https://doi.org/10.1080/19488300.2011.631096

Jabalia, N. (2018). *Bioinformatics Resources* (pp. 129–148).

Jegg, A. M., Ward, T. M., Iorns, E., Hoe, N., Zhou, J., Liu, X., Singh, S., Landgraf, R., & Pegram, M. D. (2012). PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. *Breast Cancer Research and Treatment*, *136*(3), 683–692. https://doi.org/10.1007/s10549-012-2252-9

Jeon, Y. W., & Suh, Y. J. (2013). Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. *Oncology Reports*, *29*(2), 819–825. https://doi.org/10.3892/or.2012.2158

Ji, K., Liu, C., Liu, Z., Deng, Y., & Hou, T. (2023). *Comprehensive assessment of nine target prediction web services : which should we choose for target fishing ? 24*(January), 1–15.

Jia-qi, S. U. I., Kun-peng, X. I. E., & Ming-jie, X. I. E. (2016). *Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor*. *68*(2013), 27–34. https://doi.org/10.13294/j.aps.2016.0005

Jiang, H., & Rugo, H. S. (2015). Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: How the latest results are improving therapeutic options. *Therapeutic Advances in Medical Oncology*, *7*(6), 321–339. https://doi.org/10.1177/1758834015599389

Jiang, W., & Ji, M. (2019). Receptor tyrosine kinases in PI3K signaling: The

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

therapeutic targets in cancer. *Seminars in Cancer Biology*, *59*(September 2018), 3–22. https://doi.org/10.1016/j.semcancer.2019.03.006

Johnson, D. E., Keefe, R. A. O., & Grandis, J. R. (2019). *HHS Public Access*. *15*(4), 234–248. https://doi.org/10.1038/nrclinonc.2018.8.Targeting

Johnson, G. L. (2007). *NIH Public Access*. *1773*(8), 1341–1348.

Kacan, T., Altun, A., Altun, G. G., Kacan, S. B., Sarac, B., Seker, M. M., Bahceci, A., & Babacan, N. (2014). *Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells*. *15*, 3185–3189.

Kaczyn, A. (2017). *Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells*. 271–280. https://doi.org/10.1007/s12282-016-0700-9

Kanayama, K., Imai, H., Usugi, E., Matsuda, C., Ichishi, M., Hirokawa, Y. S., & Watanabe, M. (2020). Cancer-related gene mutations and intratumoral genetic heterogeneity in human epidermal growth factor receptor 2 heterogeneous gastric cancer. *Pathology International*, *70*(11), 865–870. https://doi.org/10.1111/pin.13004

Katz, D., Ito, E., Lau, K. S., Mocanu, J. D., Bastianutto, C., Schimmer, A. D., & Liu, F. F. (2008). Increased efficiency for performing colony formation assays in 96-well plates: Novel applications to combination therapies and high-throughput screening. *BioTechniques*, *44*(2), 9–14. https://doi.org/10.2144/000112757

Khelwatty, S. A., Essapen, S., Bagwan, I., Green, M., Seddon, A. M., & Modjtahedi, H. (2014). Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. *PLoS ONE*, *9*(3), 1–10. https://doi.org/10.1371/journal.pone.0091139

Khinai, F. (2020). *Molecular classi fi cation of breast cancer : A retrospective cohort study*. *49*(October 2019), 44–48.

Kim, J., Kim, J. Y., Lee, H. B., Lee, Y. J., Seong, M. K., Paik, N., Park, W. C., Park, S., Jung, S. P., & Bae, S. Y. (2020). Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type. *Breast Cancer Research and Treatment*, *184*(2), 527–542. https://doi.org/10.1007/s10549-020-05861-6

Kim, S.-H., Shin, K.-J., Kim, D., Kim, Y.-H., Han, M. S., Lee, T. G., Kim, E., Ryu, S. H., & Suh, P.-G. (2003). Luteolin inhibits the nuclear factor-κB transcriptional activity in Rat-1 fibroblasts. *Biochemical Pharmacology*, *66*(6), 955–963. https://doi.org/https://doi.org/10.1016/S0006-2952(03)00465-9

Kim, S. (2017). *HHS Public Access*. *11*(9), 843–855.

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

https://doi.org/10.1080/17460441.2016.1216967.Getting

Kim, T., Lim, S. T., Choi, H. S., Cho, I., Noh, H., & Lee, J. (2025). *Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer*. 1–8.

Kolenda, T., Ryś, M., Guglas, K., Teresiak, A., & Bliźniak, R. (n.d.). *Basic research Quantification of long non-coding RNAs using qRT-PCR : comparison of different cDNA synthesis methods and RNA stability*.

Krystel-Whittemore, M., & Wen, H. Y. (2022). Update on HER2 expression in breast cancer. *Diagnostic Histopathology*, *28*(3), 170–175. https://doi.org/10.1016/j.mpdhp.2022.01.001

Kuhn, M., Mering, C. Von, Campillos, M., & Jensen, L. J. (2008). *STITCH : interaction networks of chemicals and proteins*. *36*(December 2007), 684–688. https://doi.org/10.1093/nar/gkm795

Kuhn, M., Szklarczyk, D., Franceschini, A., Campillos, M., Von Mering, C., Jensen, L. J., Beyer, A., & Bork, P. (2009). STITCH 2: An interaction network database for small molecules and proteins. *Nucleic Acids Research*, *38*(SUPPL.1), 552–556. https://doi.org/10.1093/nar/gkp937

Kuhn, M., Szklarczyk, D., Pletscher-frankild, S., Blicher, T. H., Mering, C. Von, Jensen, L. J., & Bork, P. (2014). *STITCH 4 : integration of protein – chemical interactions with user data*. *42*(November 2013), 401–407. https://doi.org/10.1093/nar/gkt1207

Kumar, S., & Kumar, S. (2019). *Chapter 6 - Molecular Docking: A Structure-Based Approach for Drug Repurposing* (K. B. T.-I. S. D. D. Roy (ed.); pp. 161–189). Academic Press. https://doi.org/https://doi.org/10.1016/B978-0-12-816125-8.00006-7

L. Bu, H. Wang, J. Pan, L. Chen, F. Xing, J. Wu, S. Li, D. G. (2021). *PTEN suppresses tumorigenesis by directly dephosphorylating Akt*. *November 2020*, 2020–2022. https://doi.org/10.1038/s41392-021-00571-x

Lattrich, C., Juhasz-boess, I., Ortmann, O., & Treeck, O. (2008). *Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor ß1*. *2*, 811–817.

Lee, E., Oh, S., & Sung, M. (2012). Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. *Food and Chemical Toxicology*, *50*(11), 4136–4143. https://doi.org/10.1016/j.fct.2012.08.025

Lee, J., Park, S. H., Lee, J., Chun, H., Choi, M. K., Yoon, J. H., Pham, T. H., Kim, K. H., Kwon, T., Ryu, H. W., Oh, S. R., & Yoon, D. Y. (2019). Differential effects of luteolin and its glycosides on invasion and apoptosis in MDA-MB-231 triple-negative breast cancer cells. *EXCLI Journal*, *18*, 750–763. https://doi.org/10.17179/excli2019-1459

Lee, A. V, Oesterreich, S., & Davidson, N. E. (2015). *MCF-7 Cells — Changing*

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

the Course of Breast Cancer Research and Care for 45 Years. *107*, 1–4. https://doi.org/10.1093/jnci/djv073

Li, T., Fu, X., Liu, B., Wang, X., Li, J., Zhu, P., Niu, X., Bai, J., Liu, Y., Lu, X., & Yu, Z. (2022). Luteolin binds Src , promotes STAT3 protein ubiquitination and exerts anti-melanoma effects in cell and mouse models. *Biochemical Pharmacology*, *200*(April), 115044. https://doi.org/10.1016/j.bcp.2022.115044

Lin, D. A. N., Kuang, G. E., Wan, J., Zhang, X., Li, H., Gong, X. I. A., & Li, H. (2017). *Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β - catenin expression*. 895–902. https://doi.org/10.3892/or.2016.5311

Lin, L., Chiu, S., Wu, M., Chen, P., & Yen, J. (2012). *Luteolin Induces microRNA-132 Expression and Modulates Neurite Outgrowth in PC12 Cells*. *7*(8). https://doi.org/10.1371/journal.pone.0043304

Lin, Y., Shi, R., & Wang, X. (2009). *Luteolin, a flavonoid with potentials for cancer prevention and therapy*. *8*(7), 634–646.

Liu, X., Zhang, X., Shao, Z., Zhong, X., Ding, X., Wu, L., Chen, J., He, P., Cheng, Y., Zhu, K., Zheng, D., Jing, J., & Luo, T. (2023). Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer. *Signal Transduction and Targeted Therapy*, *8*(1). https://doi.org/10.1038/s41392-023-01689-w

Loibl, S., & Gianni, L. (2017). HER2-positive breast cancer. *The Lancet*, *389*(10087), 2415–2429. https://doi.org/10.1016/S0140-6736(16)32417-5

López-lázaro, M. (2009). *Distribution and Biological Activities of the Flavonoid Luteolin*. *9*, 31–59.

Lüftner, D., & Peipp, M. (2021). New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer. *Geburtshilfe Und Frauenheilkunde*, *81*(6), 666–678. https://doi.org/10.1055/a-1471-4063

Magura, J., Moodley, R., & Mackraj, I. (2022). The effect of hesperidin and luteolin isolated from Eriocephalus africanus on apoptosis, cell cycle and miRNA expression in MCF-7. *Journal of Biomolecular Structure & Dynamics*, *40*(4), 1791–1800. https://doi.org/10.1080/07391102.2020.1833757

Mahtani, R., Holmes, F. A., Badve, S., Caldera, H., Coleman, R., Mamounas, E., Kalinsky, K., Kittaneh, M., Lower, E., Pegram, M., Press, M. F., Rugo, H. S., Schwartzberg, L., & Vogel, C. (2020). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. *Clinical Breast Cancer*, *20*(3), e251–e260. https://doi.org/10.1016/j.clbc.2019.08.001

Manuscript, A. (2015). *PubChem applications in drug discovery : a bibliometric analysis*. *19*(11), 1751–1756.

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

https://doi.org/10.1016/j.drudis.2014.08.008.PubChem

Mathew, S. P., Avaronnan, M., Devi, N., & Shenoy V.P, P. K. (2024). Her2 positive metastatic breast cancer treated with low dose lapatinib in a resource-constrained setting in South India: a retrospective audit. *Ecancermedicalscience*, *18*, 1–11. https://doi.org/10.3332/ecancer.2024.1758

Matsuda, S., Nakanishi, A., Wada, Y., & Kitagishi, Y. (2013). *Roles of PI3K / AKT / PTEN Pathway as a Target for Pharmaceutical Therapy*. *2*, 23–29.

Milella, M., Falcone, I., Conciatori, F., Incani, U. C., Curatolo, A. Del, Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., & Ciuffreda, L. (2015). *PTEN : multiple functions in human malignant tumors*. *5*(February), 1–14. https://doi.org/10.3389/fonc.2015.00024

Mimmack, M. L., Brooking, J., & Bahn, S. (2004). Quantitative polymerase chain reaction: Validation of microarray results from postmortem brain studies. *Biological Psychiatry*, *55*(4), 337–345. https://doi.org/10.1016/j.biopsych.2003.09.007

Mohammed, A. A. (2021). Prognostic parameter differences in breast cancer patients between luminal A and luminal B types after application of the new classification according to Ki67 score. *International Journal of Surgery Open*, *34*, 100357. https://doi.org/10.1016/j.ijso.2021.100357

Monti, E., Marras, E., Prini, P., & Gariboldi, M. B. (2020). Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells. *European Journal of Pharmacology*, *881*(May), 173210. https://doi.org/10.1016/j.ejphar.2020.173210

Muhammed, M. T., & Aki-yalcin, E. (2024). *Molecular Docking: Principles, Advances, and its Applications in Drug Discovery*. 480–495. https://doi.org/10.2174/1570180819666220922103109

Nardin, S., Ruelle, T., Giannubilo, I., & Del Mastro, L. (2024). Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy. *Tumori*, *110*(3), 162–167. https://doi.org/10.1177/03008916231216830

Nassar, A., Pooja, A., & Chivukula, M. (2020). HER2 testing across practices—Have we come to a consensus on the ideal method of testing? A systematic literature review. *Breast Journal*, *26*(6), 1185–1188. https://doi.org/10.1111/tbj.13867

Ng, C. K. Y., Martelotto, L. G., Gauthier, A., Wen, H. C., Piscuoglio, S., Lim, R. S., Cowell, C. F., Wilkerson, P. M., Wai, P., Rodrigues, D. N., Arnould, L., Geyer, F. C., Bromberg, S. E., Lacroix-Triki, M., Penault-Llorca, F., Giard, S., Sastre-Garau, X., Natrajan, R., Norton, L., … Reis-Filho, J. S. (2015). Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. *Genome Biology*, *16*(1), 1–21. https://doi.org/10.1186/s13059-015-0657-6

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bloinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Nickel, J., Gohlke, B., Erehman, J., Banerjee, P., Rong, W. W., Goede, A., Dunkel, M., & Preissner, R. (2014). *SuperPred : update on drug classification and target prediction*. *42*(May), 26–31. https://doi.org/10.1093/nar/gku477

Ning, G., Zhu, Q., Kang, W., Lee, H., Maher, L., Suh, Y. S., Michaud, M., Silva, M., Kwon, J. Y., Zhang, C., & Lee, C. (2021). A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. *BMC Cancer*, *21*(1), 1–17. https://doi.org/10.1186/s12885-021-08283-9

Õ, M. O., Amberger, J., Bocchini, C. A., Scott, A. F., & Hamosh, A. (2009). *McKusick ' s Online Mendelian Inheritance*. *37*(October 2008), 793–796. https://doi.org/10.1093/nar/gkn665

Odhiambo, P., Okello, H., Wakaanya, A., Wekesa, C., & Okoth, P. (2023). Mutational signatures for breast cancer diagnosis using artificial intelligence. *Journal of the Egyptian National Cancer Institute*, *35*(1). https://doi.org/10.1186/s43046-023-00173-4

Oh, S., Ju, J., Yang, W., Lee, K., Nam, K., & Shin, I. (2015). EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. *ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS*, *575*, 69–76. https://doi.org/10.1016/j.abb.2015.04.008

Ozaki Toshinori & Akira Nakagawara. (2011). *Role of p53 in Cell Death and Human Cancers*. 994–1013. https://doi.org/10.3390/cancers3010994

Pandurangan, A. K., & Esa, N. M. (2014). Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: A review. *Asian Pacific Journal of Cancer Prevention*, *15*(14), 5501–5508. https://doi.org/10.7314/APJCP.2014.15.14.5501

Pantsar, T., & Poso, A. (2018). *Binding Affinity via Docking : Fact and Fiction*. 1–11. https://doi.org/10.3390/molecules23081899

Papanikolaou, V., Stefanou, N., & Dubos, S. (2014). *Synergy of leptin / STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes*. https://doi.org/10.1007/s13402-014-0213-5

Paul, B., Trovato, J. A., & Thompson, J. (2008). Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer. *American Journal of Health-System Pharmacy*, *65*(18), 1703–1710. https://doi.org/10.2146/ajhp070646

Pflaum, J., Schlosser, S., & Müller, M. (2014). *p53 family and cellular stress responses in cancer*. *4*(October), 1–15. https://doi.org/10.3389/fonc.2014.00285

Pinzi, L., & Rastelli, G. (2019). *Molecular Docking : Shifting Paradigms in Drug Discovery*.

Prasher, P., Sharma, M., Singh, S. K., Gulati, M., Chellappan, D. K., Zacconi, F., Rubis, G. De, Gupta, G., Rad, J. S., & Cho, W. C. (2022). Luteolin : a flavonoid with a multifaceted anticancer potential. *Cancer Cell International*,

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

1–11. https://doi.org/10.1186/s12935-022-02808-3

Qi, S. (2020). *Multiple Bioinformatics Analyses of Integrated Gene Expression Profiling Data and Verification of Hub Genes Associated with Diabetic Retinopathy*. 1–12. https://doi.org/10.12659/MSM.923146

Rafehi, H., Orlowski, C., Georgiadis, G. T., Ververis, K., El-Osta, A., & Karagiannis, T. C. (2011). Clonogenic assay: Adherent cells. *Journal of Visualized Experiments*, *49*, 1–4. https://doi.org/10.3791/2573

Rajkhowa, S., & Deka, R. C. (2016). Protein-ligand docking methodologies and its application in drug discovery. In *Oncology: Breakthroughs in Research and Practice* (Vols. 2–2, pp. 891–914). https://doi.org/10.4018/978-1-5225-0549-5.ch035

Rothschild, H. T., Clelland, E., Patterson, A., Molina-Vega, J., Kaur, M., Symmans, W. F., Schwartz, C. J., Chien, A. J., & Mukhtar, R. A. (2023). HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. *Breast Cancer Research and Treatment*, *199*(2), 349–354. https://doi.org/10.1007/s10549-023-06927-x

Ruiz-Saenz, A., Dreyer, C., Campbell, M. R., Steri, V., Gulizia, N., & Moasser, M. M. (2018). HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3. *Cancer Research*, *78*(13), 3645–3658. https://doi.org/10.1158/0008-5472.CAN-18-0430

Safran, M., Dalah, I., Alexander, J., Rosen, N., Stein, T. I., Shmoish, M., Nativ, N., Bahir, I., Doniger, T., Krug, H., Sirota-madi, A., Olender, T., Golan, Y., Stelzer, G., Harel, A., & Lancet, D. (2010). *Database update GeneCards Version 3 : the human gene integrator*. *2010*, 1–16. https://doi.org/10.1093/database/baq020

Salerno, K. E., & Mix, M. D. (2018). Radiation Therapy for Locally Advanced Breast Cancer. *The Breast*, 726-735.e2. https://doi.org/10.1016/b978-0-323-35955-9.00053-2

Sato, Y., Sasaki, N., Saito, M., Endo, N., Kugawa, F., & Ueno, A. (2015). *Luteolin Attenuates Doxorubicin-Induced Cytotoxicity to MCF-7 Human Breast Cancer Cells*. *38*(5), 703–709.

Schie, E. H. Van, Amerongen, R. Van, & Alexander, C. (2020). *Aberrant WNT / CTNNB1 Signaling as a Therapeutic Target in Human Breast Cancer : Weighing the Evidence*. *8*(January), 1–14. https://doi.org/10.3389/fcell.2020.00025

Seelinger, G., Merfort, I., Wölfle, U., & Schempp, C. M. (2008). Anti-carcinogenic effects of the flavonoid luteolin. *Molecules*, *13*(10), 2628–2651. https://doi.org/10.3390/molecules13102628

Shi, R., Cao, Z., Li, J., & Ji, R. (2025). *Targeting the Wnt / b -catenin pathway and epithelial- mesenchymal transition in gastric cancer : mechanisms , therapeutic strategies , and clinical challenges*. *August*, 1–12.

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

https://doi.org/10.3389/fonc.2025.1633699

Shi, Y., & Paluch, B. E. (2012). *PTEN at a glance*. *1997*. https://doi.org/10.1242/jcs.093765

Shuch, Brian; Linehan, B. W. M.L.; Srivasan, R. (2012). *O ncologist G*. *0031*(0), 1051–1062. https://doi.org/10.1634/theoncologist.2011-0227

Siddiqa, A., Long, L. M., Li, L., Marciniak, R. A., & Kazhdan, I. (2008). *anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signalling pathways*. *8*, 1–8. https://doi.org/10.1186/1471-2407-8-129

Song, M. S., Salmena, L., & Pandolfi, P. P. (2012). The functions and regulation of the PTEN tumour suppressor. *Nature Publishing Group*, *13*(5), 283–296. https://doi.org/10.1038/nrm3330

Stelzer, G., Dalah, I., Stein, T. I., Satanower, Y., Rosen, N., Nativ, N., Oz-levi, D., Olender, T., Belinky, F., Bahir, I., Krug, H., Perco, P., Mayer, B., Kolker, E., & Safran, M. (2011). *In-silico human genomics with GeneCards*. *5*(6), 709–717.

Stránský, D., Šteigerová, M., Kuklová, M., Canová, N., Novotný, J., & Šenolt, L. (2025). *synthesis method from cell cultures*.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Swain, S. M., Shastry, M., & Hamilton, E. (2023). Targeting HER2-positive breast cancer: advances and future directions. *Nature Reviews Drug Discovery*, *22*(2), 101–126. https://doi.org/10.1038/s41573-022-00579-0

Sylvia S. Gayle, Samuel L.M. Arnold, Ruth M. O'Regan, and R. N. (2013). *Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance*. *12*(2), 151–162.

Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., & Von Mering, C. (2019). STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research*, *47*(D1), D607–D613. https://doi.org/10.1093/nar/gky1131

Szklarczyk, D., Santos, A., Mering, C. Von, Jensen, L. J., Bork, P., & Kuhn, M. (2016). *STITCH 5 : augmenting protein – chemical interaction networks with tissue and affinity data*. *44*(November 2015), 380–384. https://doi.org/10.1093/nar/gkv1277

Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., & Nakagawa, K. (2011). Roles of BIM induction and survivin downregulation in lapatinib-

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

induced apoptosis in breast cancer cells with HER2 amplification. *Oncogene*, *30*(39), 4097–4106. https://doi.org/10.1038/onc.2011.111

Tena, D. J. D., Burgos-Morón, M. E., Calderón-Montaño, M. J. M., Sanz, D. I., Sainz, D. J., Dr. Migu, D. M. L.-L., & Lopez-Lazaro, D. M. (2013). *Consumption of the Dietary Flavonoids Quercetin , Luteolin a ... Página 1 de 5 Meta analysis Consumption of the Dietary Flavonoids Quercetin , Luteolin and Kaempferol and Overall Risk of Cancer - A Review and Meta-Analysis of the Epidemiological Data Cons*. *2007*, 5–9.

Trowe, T., Boukouvala, S., Calkins, K., Cutler, R. E., Fong, R., Funke, R., Gendreau, S. B., Kim, Y. D., Miller, N., Woolfrey, J. R., Vysotskaia, V., Jing, P. Y., Gerritsen, M. E., Matthews, D. J., Lamb, P., & Heuer, T. S. (2008). EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. *Clinical Cancer Research*, *14*(8), 2465–2475. https://doi.org/10.1158/1078-0432.CCR-07-4367

Tsapralis, D., Panayiotides, I., Peros, G., Liakakos, T., & Karamitopoulou, E. (2012). Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. *World Journal of Gastroenterology*, *18*(2), 150–155. https://doi.org/10.3748/wjg.v18.i2.150

Tuorkey, M. J. (2016). Molecular targets of luteolin in cancer. *European Journal of Cancer Prevention : The Official Journal of the European Cancer Prevention Organisation (ECP)*, *25*(1), 65–76. https://doi.org/10.1097/CEJ.0000000000000128

Uesaka, K., Oka, H., Kato, R., Kanie, K., Kojima, T., Tsugawa, H., Toda, Y., & Horinouchi, T. (2022). Bioinformatics in bioscience and bioengineering: Recent advances, applications, and perspectives. *Journal of Bioscience and Bioengineering*, *134*(5), 363–373. https://doi.org/10.1016/j.jbiosc.2022.08.004

Ulrich, L., & Okines, A. F. C. (2021). Treating advanced unresectable or metastatic HER2-positive breast cancer: A spotlight on tucatinib. *Breast Cancer: Targets and Therapy*, *13*, 361–381. https://doi.org/10.2147/BCTT.S268451

Wang, H. (2014). Lapatinib for the treatment of breast cancer in the people's Republic of China. *OncoTargets and Therapy*, *7*, 1367–1373. https://doi.org/10.2147/OTT.S60586

Wang, S., Chen, Y., Chow, J., Chien, M., Yang, F., Wen, Y., Lee, W., Tseng, T., City, N. T., Medical, K., Shan, C., Hospital, W. F., Hospital, W. F., Medical, T., Medical, T., & Medical, T. (2018). *Stimulation of Fas / FasL-mediated apoptosis by luteolin through enhancement of histone H3 acetylation and c-Jun activation in HL-60*. *March*, 1–44. https://doi.org/10.1002/mc.22807

Wang, S., Yu, L., Shi, W., & Li, X. (2018). *Prognostic roles of signal transducers and activators of transcription family in human breast cancer*. *0*(January), 1–11.

Wang, Y., Wang, J., Gong, X., Wen, X., & Gu, X. (2018). *Review Article Luteolin :*

UNIVERSITAS
GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara
HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Anti-breast Cancer Effects and Mechanisms. *3*(1), 85–90. https://doi.org/10.14218/JERP.2018.00011

Weng, Y., Liang, W., & Ji, Y. (2021). *Key Genes and Prognostic Analysis in HER2 þ Breast Cancer*. *20*, 1–14. https://doi.org/10.1177/1533033820983298

Witters, L. M., Santala, S. M., Engle, L., Chinchilli, V., Ph, D., & Lipton, A. (2003). *Decreased Response to Paclitaxel Versus Docetaxel in HER-2 / neu Transfected Human Breast Cancer Cells*. *26*(1), 50–54.

Wu, H., Lin, J., Liu, Y., Chen, H., Hsu, K., Lin, S., Peng, K., Lin, K., Hsieh, C., & Chen, D. (2021). Phytomedicine Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT / mTOR signaling pathway. *Phytomedicine*, *81*, 153437. https://doi.org/10.1016/j.phymed.2020.153437

Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., Harris, J., & Spector, N. L. (2006). A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, *103*(20), 7795–7800. https://doi.org/10.1073/pnas.0602468103

Xiang, Z., Song, S., Zhu, Z., Sun, W., Gifts, J. E., Sun, S., Li, Q. S., Yu, Y., & Li, K. K. (2019). LncRNAs GIHCG and SPINT1-AS1 are crucial factors for pan-cancer cells sensitivity to lapatinib. *Frontiers in Genetics*, *10*(feburay). https://doi.org/10.3389/fgene.2019.00025

Yao, Z., Dong, J., Zhu, Y. C. M., & Wen, M. (2016). TargetNet : a web service for predicting potential drug – target interaction profiling via multi-target SAR models. *Journal of Computer-Aided Molecular Design*, *30*(5), 413–424. https://doi.org/10.1007/s10822-016-9915-2

Ye, M., Huang, W., Liu, R., Kong, Y., Liu, Y., Chen, X., & Xu, J. (2021). Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. *Frontiers in Pharmacology*, *12*(July), 1–13. https://doi.org/10.3389/fphar.2021.651516

Yi, H., Li, Z., Liu, X., Dai, S., & Li, S. (2021). Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer. *Evidence-Based Complementary and Alternative Medicine*, *2021*. https://doi.org/10.1155/2021/9933274

Yin, Q., Wang, L., Yu, H., Chen, D., & Zhu, W. (2021). *Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway*. *12*(September), 1–18. https://doi.org/10.3389/fphar.2021.716672

Yoo, H. S., Won, S. B., & Kwon, Y. H. (2021). Luteolin Induces Apoptosis and Autophagy in HCT116 Colon Cancer Cells via p53-Dependent Pathway Luteolin Induces Apoptosis and Autophagy in HCT116 Colon Cancer Cells

UNIVERSITAS GADJAH MADA
Identifikasi Gen Target Potensial Luteolin Dalam Mengatasi Resistensi Lapatinib Pada Kanker Payudara HER2+: Studi Bioinformatika dan IN Vitro
Sri Rahmayani Ningsih, Bioinformatics, Breast cancer, Luteolin, Lapatinib, MCF-7/HER2.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

via. *Nutrition and Cancer*, *0*(0), 1–10. https://doi.org/10.1080/01635581.2021.1903947

Zhang, L., Liu, Q., Huang, L., Yang, F., Liu, A., & Zhang, J. (2020). Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. *Biochemical and Biophysical Research Communications*, *531*(3), 364–371. https://doi.org/10.1016/j.bbrc.2020.07.049

Zhang, W., Ding, W., Chen, Y., Feng, M., Ouyang, Y., Yu, Y., & He, Z. (2011). *Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K / Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells*. *43*(8), 647–653. https://doi.org/10.1093/abbs/gmr050.Advance

Zhang, Y., Li, H., Shang, S., Meng, S., Lin, T., Zhang, Y., & Liu, H. (2021). Evaluation validation of a qPCR curve analysis method and conventional approaches. *BMC Genomics*, *22*, 1–12. https://doi.org/10.1186/s12864-021-07986-4

Zhao, M., Howard, E. W., Parris, A. B., Guo, Z., Zhao, Q., Ma, Z., Xing, Y., Liu, B., Edgerton, S. M., & Thor, A. D. (2017). *Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells*. *8*(35), 58847–58864.

Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., & Wang, Z. (2024). *The Biological Roles and Clinical Applications of the PI3K / AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer : A Comprehensive Review*.

Zhong, L., Xiang, X., Ye, J., Lu, W., Lv, J., Zhang, D., Xia, B., Zhou, P., & Wang, L. (2014). *Application of the MCF-7 Breast Cancer Cells in Endocrine-disrupting Area*. *959*, 928–935. https://doi.org/10.4028/www.scientific.net/AMR.955-959.928

Zhu, M., Sun, Y., Su, Y., Guan, W., Wang, Y., Han, J., Wang, S., Yang, B., Wang, Q., & Kuang, H. (2024). Luteolin: A promising multifunctional natural flavonoid for human diseases. *Phytotherapy Research*, *38*(7), 3417–3443. https://doi.org/10.1002/ptr.8217